Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure

Biochemical Pharmacology

Volumn 69, Issue 5, 2005, Pages 725-732

  Szenczi, Orsolya ^a   Kemecsei, Péter ^a   Holthuijsen, Max F J ^a,b   Van Riel, Natal A W ^b   Van Der Vusse, Ger J ^c   Pacher, Pál ^d   Szabó, Csaba ^a,d   Kollai, Márk ^a   Ligeti, László ^a   Ivanics, Tamás ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d INOTEK CORPORATION   (United States)

Author keywords

Adriamycin; Calcium; Heart failure; Peroxynitrite; Poly(ADP ribose) polymerase (PARP); Superoxide

Indexed keywords

CALCIUM; DOXORUBICIN; HYDROGEN PEROXIDE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHENANTHRIDINONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EXPOSURE; HEART BEAT; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART PERFUSION; IN VITRO STUDY; ISOLATED HEART; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

EID: 13844264114     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.11.023     Document Type: Article

References (32)

1. L. Virag, and C. Szabo The therapeutic potential of poly(ADP-ribose) polymerase inhibitors Pharmacol Rev 54 2002 375 429
2. G. Szabo, L. Liaudet, S. Hagl, and C. Szabo Poly(ADP-ribose) polymerase activation in the reperfused myocardium Cardiovasc Res 61 2004 471 480
3. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 2004 185 229
4. G. Minotti, S. Recalcati, P. Menna, E. Salvatorelli, G. Corna, and G. Cairo Links doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms Methods Enzymol 378 2004 340 361
5. B. Kalyanaraman, J. Joseph, S. Kalivendi, S. Wang, E. Konorev, and S. Kotamraju Doxorubicin-induced apoptosis: implications in cardiotoxicity Mol Cell Biochem 234-235 2002 119 124
6. E.L. De Beer, A.E. Bottone, and E.E. Voest Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review Eur J Pharmacol 415 2001 1 11
7. S. Fogli, P. Nieri, and M.C. Breschi The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage Fed Am Soc Exp Biol J 18 2004 664 675
8. P.K. Singal, N. Iliskovic, T. Li, and D. Kumar Adriamycin cardiomyopathy: pathophysiology and prevention Fed Am Soc Exp Biol J 11 1997 931 936
9. P. Pacher, L. Liaudet, P. Bai, L. Virag, J.G. Mabley, and G. Hasko Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure J Pharmacol Exp Ther 300 2002 862 867
10. P. Jagtap, F.G. Soriano, L. Virag, L. Liaudet, J. Mabley, and E. Szabo Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents Crit Care Med 30 2002 1071 1082
11. L.E. Solem, L.J. Heller, and K.B. Wallace Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin J Mol Cell Cardiol 28 1996 1023 1032
12. P. Pacher, L. Liaudet, J. Mabley, K. Komjati, and C. Szabo Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure J Am Coll Cardiol 40 2002 1006 1016
13. P. Pacher, L. Liaudet, F.G. Soriano, J.G. Mabley, E. Szabo, and C. Szabo The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes Diabetes 51 2002 514 521
14. T. Ivanics, Z. Miklos, L. Dezsi, K. Ikrenyi, A. Toth, and T.H. Roemen Concomitant accumulation of intracellular free calcium and arachidonic acid in the ischemic-reperfused rat heart Mol Cell Biochem 226 2001 119 128
15. 2+ indicators with greatly improved fluorescence properties J Biol Chem 260 1985 3440 3450
16. i in intact rabbit cardiac myocytes Biophys J 68 1995 1453 1460
17. P. Pacher, L. Liaudet, P. Bai, J.G. Mabley, P.M. Kaminski, and L. Virag Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction Circulation 107 2003 896 904
18. P. Bai, J.G. Mabley, L. Liaudet, L. Virag, C. Szabo, and P. Pacher Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity Oncol Rep 11 2004 505 508
19. P.S. Green, and C. Leeuwenburgh Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis Biochim Biophys Acta 1588 2002 94 101
20. A.C. Childs, S.L. Phaneuf, A.J. Dirks, T. Phillips, and C. Leeuwenburgh Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio Cancer Res 62 2002 4592 4598
21. 2+ release from sarcoplasmic reticulum and contractile protein function in 'chemically-skinned' rabbit ventricular trabeculae Jpn J Pharmacol 76 1998 405 413
22. E. Szabados, G.M. Fischer, K. Toth, B. Csete, B. Nemeti, and K. Trombitas Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat Free Radic Biol Med 26 1999 309 317
23. F. Rossi, W. Filippelli, S. Russo, A. Filippelli, and L. Berrino Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances Pharmacol Toxicol 75 1994 99 107
24. G. Sacco, M. Bigioni, S. Evangelista, C. Goso, S. Manzini, and C.A. Maggi Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin induced cardiotoxocity in the rat Eur J Pharmacol 414 2001 71 78
25. E.R. Schwartz, C. Pollick, J. Dow, M. Patterson, Y. Birnbaum, and R.A. Kloner A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography Cardiovasc Res 39 1998 216 223
26. X. Luo, Y. Evrovsky, D. Cole, J. Trines, L.N. Benson, and D.C. Lehotay Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat Biochim Biophys Acta 1360 1997 45 52
27. H.E. Mohamed, S.E. El-Swefy, and H.H. Hagar The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats Pharmacol Res 42 2000 115 121
28. R.F. Vidal, S. Eksborg, M. Sundberg, M. Carlberg, B. Elfsson, and B.S. Andersson Doxorubicin- and daunorubicin-induced energy deprivation and nucleotide degradation in isolated cardiomyocytes Toxicology 114 1996 1 10
29. 2+ transport proteins and the effect of taurine on myocardial protection in rabbits J Zhejiang Univ Sci 4 2003 114 120
30. H.A. Gambliel, B.E. Burke, B.J. Cusack, G.M. Walsh, Y.L. Zhang, and P.S. Mushlin Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression Biochem Biophys Res Commun 291 2002 433 438
31. R.J. Boucek Jr., A. Miracle, M. Anderson, R. Engelman, J. Atkinson, and D.A. Dodd Persistent effects of doxorubicin on cardiac gene expression J Mol Cell Cardiol 31 1999 1435 1446
32. C.Y. Xiao, M. Chen, Z. Zsengeller, H. Li, L. Kiss, and M. Kollai Poly(ADP-ribose) polymerase promotes cardiac remodeling, contractile failure and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure J Pharmacol Exp Ther Nov, 2004 [Epub ahead of print]